Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

821 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators. James ND, et al. Among authors: de bono j. Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21. Lancet. 2016. PMID: 26719232 Free PMC article. Clinical Trial.
Reversing resistance to targeted therapy.
Vidal L, Attard G, Kaye S, De Bono J. Vidal L, et al. Among authors: de bono j. J Chemother. 2004 Nov;16 Suppl 4:7-12. doi: 10.1179/joc.2004.16.Supplement-1.7. J Chemother. 2004. PMID: 15688600 Review.
Making sense of antisense.
Vidal L, Blagden S, Attard G, de Bono J. Vidal L, et al. Among authors: de bono j. Eur J Cancer. 2005 Dec;41(18):2812-8. doi: 10.1016/j.ejca.2005.06.029. Epub 2005 Nov 9. Eur J Cancer. 2005. PMID: 16289851 Review.
Update on tubulin-binding agents.
Attard G, Greystoke A, Kaye S, De Bono J. Attard G, et al. Among authors: de bono j. Pathol Biol (Paris). 2006 Mar;54(2):72-84. doi: 10.1016/j.patbio.2005.03.003. Pathol Biol (Paris). 2006. PMID: 16545633 Review.
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours.
Greystoke A, Blagden S, Thomas AL, Scott E, Attard G, Molife R, Vidal L, Pacey S, Sarkar D, Jenner A, De-Bono JS, Steward W. Greystoke A, et al. Among authors: de bono js. Ann Oncol. 2006 Aug;17(8):1313-9. doi: 10.1093/annonc/mdl097. Epub 2006 May 25. Ann Oncol. 2006. PMID: 16728482 Free article. Clinical Trial.
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.
de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, Cockey L, Mason M, Graham J. de Bono JS, et al. J Clin Oncol. 2007 Jan 20;25(3):257-62. doi: 10.1200/JCO.2006.07.0888. J Clin Oncol. 2007. PMID: 17235043 Clinical Trial.
821 results